Screening for tuberkuloseinfektion før behandling med biologiske lægemidler

Ugeskrift for Laeger

Volumn 173, Issue 12, 2011, Pages 893-896

  Ravn, Pernille ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

DRUG ANTAGONISM; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; REVIEW; RISK FACTOR; SECRETION; TUBERCULIN TEST;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOLOGIC TESTS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; RISK FACTORS; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953088303     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000;49:1-51.
2. Solovic I, Sester M, Gomez-Reino JJ et al. The risk of tuberculosis related to TNF antagonist therapies: A TBNET Consensus Statement 1. Eur Respir J 2010;36;1185-206.
3. Wallis RS, Broder MS, Wong JY et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
4. Skov L, Bendtzen K. Biologiske lægemidler til behandling af ikkecancerrelaterede sygdomme. Ugeskr Læger 2008;170:2120-6.
5. Gomez-Reino JJ, Carmona L, Valverde VR et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
6. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
7. Keane J, Gershon S, Wise RP. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
8. http://www.ssi.dk (10. jan 2011).
9. Askling J, Fored CM, Brandt L et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92.
10. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2004;1:CD000171.
11. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
12. Diel R, Hauer B, Loddenkemper R et al. Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Z Rheumatol 2009;68:411-6.
13. Sester M, Sotgiu G, Lange C et al. Interferon-( release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2010;37:100-11.
14. Ravn P, Rose MV, Søborg B et al. Ny test til diagnostik af tuberkulose. Ugeskr Læger 2009;171:2635-9.
15. Diel R, Loddenkemper R, Nienhaus A. Evidence based comparison of commercial interferon-gamma release assays for detecting active tuberculosis - a meta-analysis. Chest2010;137:952-68.
16. Aichelburg MC, Rieger A, Breitenecker F et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 2009;48:954-62.
17. Diel R, Loddenkemper R, Meywald-Walter K et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 2008;177:1164-70.
18. Søborg B, Ruhwald M, Hetland ML et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 2009;36:1876-84.
19. Belard E, Semb S, Ruhwald M et al. Prednisolone treatment affects the performance of the quantiferon gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflam Bowel Dis 2011 (i trykken).
20. Kleinert S, Kurzai O, Elias J et al. Comparison of two interferon gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2010;69:782-4.